Who
Neal Walker
Director
Company insider
Files Form 4 as: Director, Aldeyra Therapeutics; CEO, Aclaris Therapeutics.
In numbers
- Trades disclosed
- 212
- Buys
- 2
- Sells
- 13
- Bought
- $218K
- Sold
- $5.4M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 7 May 2014
- Last trade
- 9 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,318 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,318 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —63,475 | filing |
| 3 Feb 2026filed 5 Feb 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code F | $65K18,611 at $3.47 | filing |
| 3 Feb 2026filed 5 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —63,475 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —63,475 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —63,475 | filing |
| 3 Feb 2026filed 5 Feb 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code F | $65K18,611 at $3.47 | filing |
| 2 Feb 2026filed 6 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —274,800 at $0.00 | filing |
| 2 Feb 2026filed 6 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —961,700 at $0.00 | filing |
| 2 Feb 2026filed 6 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —274,800 at $0.00 | filing |
| 2 Feb 2026filed 6 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —961,700 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —29,150 | filing |
| 2 Jan 2026filed 5 Jan 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code F | $29K9,952 at $2.88 | filing |
| 2 Jan 2026filed 5 Jan 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —29,150 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —29,150 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —29,150 | filing |
| 2 Jan 2026filed 5 Jan 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code F | $29K9,952 at $2.88 | filing |
News
No headline names them, or the companies they trade most, lately.